Like many rare disorders, periodic paralysis can go undiagnosed and be easily misinterpreted as a wide variety of neurologic or other disorders. But with increased awareness of the unique symptoms of ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window VANCOUVER -- ...

More than 15 years of research led by neurologists at the University of Rochester Medical Center (URMC) has culminated in the first approved treatment for individuals with a rare neuromuscular ...

Scientists have identified a gene underlying a disease that causes temporary paralysis of skeletal muscle. The finding, they say, illustrates how investigations of rare genetic diseases can drive ...

Taro announced the launch of Keveyis (dichlorphenamide) tablets, the first therapy approved for the treatment of primary hyperkalemic and hypokalemic periodic paralysis and related variants. Keveyis ...

Thyrotoxicosis can lead to thyrotoxic periodic paralysis (TPP), an endocrine channelopathy, and is the most common cause of acquired periodic paralysis. Typically, paralytic attacks cease when ...

In the past 15 years, Ryan Csupak has been in an emergency room 30 to 40 times, unable to move his legs and arms. He’s experienced shortness of breath, extreme fatigue and weakness. This is the ...

Taro announced that the Food and Drug Administration (FDA) has approved Keveyis (dichlorphenamide) tablets for the treatment of primary hyperkalemic and hypokalemic periodic paralysis. Keveyis is the ...

Gamstorp specifically excluded clinical myotonia from her syndrome: "The typical inability to relax after a muscle contraction in myotonia congenita is not seen during or between attacks of adynamia ...

Primary Periodic Paralysis is a rare genetic condition impacting 3,000-4,000 Americans characterized by repeated episodes of extreme muscle weakness or temporary paralysis, often triggered by specific ...